Dr. Gallagher joined Frazier Healthcare’s life science team in October of 2013 as a Venture Partner. Prior to Frazier, Dr. Gallagher was President and CEO of Calistoga Pharmaceuticals, a Frazier-founded company based on a set of novel, preclinical assets spun out of Icos Pharmaceuticals. Dr. Gallagher together with an experienced team she helped to build, advanced a first-in-class product (CAL-101, now called idelalisib) through definitive, proof-of-concept studies in patients with certain lymphomas and leukemias. These efforts ultimately led to the acquisition of Calistoga by Gilead Sciences in 2011 for a total consideration of $600 million.

Dr. Gallagher currently serves on several biotech boards, including AnaptysBio and Atterocor, both of which are Frazier portfolio companies.

Dr. Gallagher attended Vanderbilt University and received Bachelor of Science and Doctor of Pharmacy degrees from the College of Pharmacy at the University of Kentucky. She started her career at Eli Lilly and Company and held roles of increasing responsibility with Amgen, Agouron/Pfizer, Biogen Idec, CancerVax and Anadys Pharmaceuticals.

Feel free to contact her at carol.gallagher@frazierhealthcare.com